# A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

> **NCT02795325** · PHASE1 · TERMINATED · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 41 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 1

## Interventions

- **DRUG:** DCR-PH1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02795325
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-13
- **Primary completion:** 2016-10-14
- **Final completion:** 2016-10-14
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795325, "A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02795325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*